Datopotamab Deruxtecan Shows Promising Activity in Heavily Pretreated Advanced HR-positive/HER2-negative and Triple-Negative Breast Cancers
Findings from the phase I TROPION-PanTumor01 study
Scorecard: Enzalutamide
- Tumour Type
- Genitourinary Cancers
- Tumour Subtype
- Prostate cancer
- Trial Name
- EMBARK
Scorecard: Mirvetuximab soravtansine-gynx
- Tumour Type
- Gynaecological Malignancies
- Tumour Subtype
- Epithelial ovarian, fallopian tube or primary peritoneal cancer
- Trial Name
- MIRASOL, Study 0416
Scorecard: Amivantamab
- Tumour Type
- Thoracic Malignancies
- Tumour Subtype
- Non-small-cell Lung Cancer
- Trial Name
- PAPILLON
EMA Recommends Extension of Indications for Amivantamab
New indication concerns combination therapy with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations